Father’s Day is just around the corner, but many dads won’t be around to celebrate. Prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer death among men in the U.S.
Defining a Radiation Target with Augmenix
The company’s SpaceOAR System is designed to temporarily separate organs during radiotherapy so that normal tissues are spared, and to mark tumor resection sites to allow for targeted therapy.
[OneMedForum] Clarient Grows Along with Cancer Testing Market
The Aliso Viejo, Calif.-based company achieved several major milestones in 2009.
ProtoxPresents Data, Awaits Key Results for PRX302
Protox Therapeutics applies genetic engineering techniques to create innovative, targeted protein-based therapeutics which are focused on prostate conditions and cancer.
Two Studies Cast Doubt On Common Prostate Cancer Test
A common prostate-cancer screening test may be largely ineffective, according to two new studies. Scientists in the U.S. and Europe found that the PSA blood test saves few lives and leads to unnecessary treatments for large numbers of men.
